La migraine en milieu scolaire a Gao ua Mali

Introduction La migraine est une maladie bénigne mais handicapante et qui peut altérer la qualité de vie des patients, perturber les relations affectives et retentir sur les activités scolaires et professionnelles. Objectifs L’objectif de notre travail était d’étudier les aspects épidémiologiques et l’impact de la migraine en milieu scolaire dans la commune urbaine de Gao au Mali. Méthodes Il s’agit d’une étude transversale réalisée chez les élèves de la ville de Gao. Le sondage a été fait par grappes dans 11 lycées dont chacun a représenté une grappe. L’étude a porté sur 733 élèves le diagnostic de migraine était retenu suivant les critères de L’International Headache Society (IHS) IHS 2004 et le GRIM. Résultats La prévalence globale de la migraine en milieu scolaire était de 17,3% (IC95% : [14,6% à 20%]). La prévalence parmi les élèves céphalalgiques était de 20%(IC95% : [16,91% à 23,09]), elle était significativement plus élevée chez les filles 23,0% que chez les garçons 14,8% (p< 0,01). Concernant son impact sur la vie scolaire, 63,8% des élèves migraineux avaient un absentéisme de 1 à 14 jours avec une moyenne de 5 jours pendant le dernier trimestre précédant l’enquête ; il y avait une limitation de la concentration chez 19,2% des élèves migraineux.Conclusion La migraine est fréquente chez les lycéens de Gao avec une prédominance féminine. Elle a un impact négatif sur le rendement scolaire du à l’absentéisme et aux troubles de la concentration. Il apparait donc important de procéder à une campagne de sensibilisation ciblée à grande échelle dans l’environnement scolaire

KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro.

Preventing relapses of Plasmodium vivax malaria through a radical cure depends on use of the 8-aminoquinoline primaquine, which is associated with safety and compliance issues. For future malaria eradication strategies, new, safer radical curative compounds that efficiently kill dormant liver stages (hypnozoites) will be essential. A new compound with potential radical cure activity was identified using a low-throughput assay of in vitro-cultured hypnozoite forms of Plasmodium cynomolgi (an excellent and accessible model for Plasmodium vivax). In this assay, primary rhesus hepatocytes are infected with P. cynomolgi sporozoites, and exoerythrocytic development is monitored in the presence of compounds. Liver stage cultures are fixed after 6 days and stained with anti-Hsp70 antibodies, and the relative proportions of small (hypnozoite) and large (schizont) forms relative to the untreated controls are determined. This assay was used to screen a series of 18 known antimalarials and 14 new non-8-aminoquinolines (preselected for blood and/or liver stage activity) in three-point 10-fold dilutions (0.1, 1, and 10 μM final concentrations). A novel compound, designated KAI407 showed an activity profile similar to that of primaquine (PQ), efficiently killing the earliest stages of the parasites that become either primary hepatic schizonts or hypnozoites (50% inhibitory concentration [IC50] for hypnozoites, KAI407, 0.69 μM, and PQ, 0.84 μM; for developing liver stages, KAI407, 0.64 μM, and PQ, 0.37 μM). When given as causal prophylaxis, a single oral dose of 100 mg/kg of body weight prevented blood stage parasitemia in mice. From these results, we conclude that KAI407 may represent a new compound class for P. vivax malaria prophylaxis and potentially a radical cure

Drug Discovery for Kinetoplastid Diseases : Future Directions

International audienceKinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases

KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission

Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle. We have previously reported the discovery of a novel class of antimalarial compounds in the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of malaria. Consistent with the previously reported activity profile of this series, the clinical candidate KAF156 shows blood schizonticidal activity with 50% inhibitory concentrations of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99% effective doses of 0.6, 0.9, and 1.4 mg/kg, respectively. When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protective as a single oral dose of 10 mg/kg. Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro and in vivo. Collectively, our data suggest that KAF156, currently under evaluation in clinical trials, has the potential to treat, prevent, and block the transmission of malaria